Research teams, sponsors and CROs comparing data collection for clinical trials, from focused participant-centered studies to complex multi-site protocols.
Scope Dedicated EDC systems and participant-centered clinical-trial data collection are compared by their documented capabilities. Whether a participant-centered platform also needs a dedicated EDC depends on in-visit data entry, clinical queries, coding, verification and database-management requirements, rather than study size or trial phase alone.
These notes describe the products in the EDC guide.
Castor
Best for
Academic groups, biotechs and device teams running investigator-initiated or mid-size studies who want to build studies themselves.
What to consider
Castor has a large published study footprint and strong certifications, and teams can build studies without vendor help. It offers fewer native modules than the enterprise suites, and Everest Group placed it as a Major Contender rather than a Leader in 2024.
Large sponsors and CROs that want data collection and randomization and supply management on one Oracle platform.
What to consider
Clinical One unifies EDC and RTSM and has a well-documented API. Public information gaps include a study count, a Part 11 statement specific to Clinical One and prices; we could not find these in the sources checked.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Castor vs Oracle Clinical One (EDC): category feature evidence and sources. Products are not ranked.
Category feature
Castor
Oracle Clinical One
Track record in regulated multi-site trialsFeature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Castor
Extended support
Castor reports more than 31,900 studies with 9.5 million participants in 171 countries, but its pages give no evidence of global Phase III programs.
An analyst assessment does not establish product adoption or a named trial deployment.
Unknown does not mean unavailable. The public evidence does not establish support under this category’s definition.
Study build and mid-study changesFeature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Castor
Supported
Castor offers self-service build with a low-code eCRF builder and reusable templates, and says forms can be edited mid-study with audit trails and separate test environments, without a no-downtime claim.
Self-build and audited mid-study edits are stated; uninterrupted live use is not claimed.
Oracle Clinical One
Supported
Oracle documents versioned changes to live studies, including Advanced Study Versioning and several versions in production, but we could not load an Oracle page that states changes run without downtime.
Trial standards and ISO certification are listed; public certificate or report access is not established.
Oracle Clinical One
Supported
Oracle documents electronic signatures and audit-trail datasets for Clinical One, and its cloud compliance page lists ISO 27001 attestations by line of business, but we found no public Part 11 statement specific to Clinical One.
eConsent, ePRO/eCOA and eSource establish connected modules; native supply and coding are not listed.
Oracle Clinical One
Supported
Clinical One combines data collection with randomization and trial supply management, Central Coding and Analytics; eCOA and eConsent come through partner integrations.